Peter Keen
Angel Investor
Cambridge, United States
Peter Keen is a seed investor in Cambridge focused on Biopharma and E-Commerce. Peter Keen - Independent Investment Committee Member @ British Patient Capital
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Peter Keen invests in
Stages Peter Keen invests in
Countries Peter Keen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biopharma 1 (25%)
- E-Commerce 1 (25%)
- Web Design 1 (25%)
- Health Care 1 (25%)
- Pharmaceutical 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SupaPass is an all-in-one website and app creation platform for any business to launch its own website and apps. SupaPass allows anyone to create beautiful and powerful, payment-ready, all-in-one content website and mobile apps instantly without any technical knowledge.With millions of individuals and businesses globally needing a launch-ready,affordable content driven website and app, SupaPass is an innovative white-label platform that allows clients to retain 100% of sales and full ownership of customer data at the touch of a button. It offers more cost-effective and intuitive designs to make content such as podcasts, video, audio and streaming channels more manageable, it is over 10 times faster and cheaper than custom-built solutions.With SupaPass’s technology clients are able to keep their own brand front and control how they interact with their customers. With a content layout similar to Netflix and Prime, SupaPass gives clients the tools they need to have everything in one place to grow their business online. It services a wide range of sectors and verticals including Podcasting, Fitness, and Wellbeing, TV and Film, Archives, Membership Organisations, Music, Sport, Charities, Conferences, and Consultancies.SupaPass was founded in 2011. | $618.5K / Seed / Mar 30, 2020 | ||
| Small Pharma applies expert intellectual property design to guide academic discovery to commercial product. We operate a scalable model of outsourced drug development. We assemble specific expert teams to design and execute development programs with demonstrated track-records in all disciplines essential to their success. | $1.1M / Seed / Apr 10, 2017 | ||
| SupaPass is an all-in-one website and app creation platform for any business to launch its own website and apps. SupaPass allows anyone to create beautiful and powerful, payment-ready, all-in-one content website and mobile apps instantly without any technical knowledge.With millions of individuals and businesses globally needing a launch-ready,affordable content driven website and app, SupaPass is an innovative white-label platform that allows clients to retain 100% of sales and full ownership of customer data at the touch of a button. It offers more cost-effective and intuitive designs to make content such as podcasts, video, audio and streaming channels more manageable, it is over 10 times faster and cheaper than custom-built solutions.With SupaPass’s technology clients are able to keep their own brand front and control how they interact with their customers. With a content layout similar to Netflix and Prime, SupaPass gives clients the tools they need to have everything in one place to grow their business online. It services a wide range of sectors and verticals including Podcasting, Fitness, and Wellbeing, TV and Film, Archives, Membership Organisations, Music, Sport, Charities, Conferences, and Consultancies.SupaPass was founded in 2011. | $548K / Seed / Dec 04, 2015 | ||
| SupaPass is an all-in-one website and app creation platform for any business to launch its own website and apps. SupaPass allows anyone to create beautiful and powerful, payment-ready, all-in-one content website and mobile apps instantly without any technical knowledge.With millions of individuals and businesses globally needing a launch-ready,affordable content driven website and app, SupaPass is an innovative white-label platform that allows clients to retain 100% of sales and full ownership of customer data at the touch of a button. It offers more cost-effective and intuitive designs to make content such as podcasts, video, audio and streaming channels more manageable, it is over 10 times faster and cheaper than custom-built solutions.With SupaPass’s technology clients are able to keep their own brand front and control how they interact with their customers. With a content layout similar to Netflix and Prime, SupaPass gives clients the tools they need to have everything in one place to grow their business online. It services a wide range of sectors and verticals including Podcasting, Fitness, and Wellbeing, TV and Film, Archives, Membership Organisations, Music, Sport, Charities, Conferences, and Consultancies.SupaPass was founded in 2011. | $763K / Seed / Nov 06, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Peter Keen invest in?
Peter Keen invests primarily in Biopharma, E-Commerce and Web Design startups, most often at Seed stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peter Keen?
Public channels for Peter Keen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Peter Keen last invest?
The most recent investment recorded for Peter Keen closed in Mar 2020. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
